Taysha Gene Therapies (TSHA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Amendment filed solely to add missing Inline XBRL data tagging; no other changes made.
Executive compensation and say-on-pay
Stock options and awards are granted to employees and directors, with annual refresh grants typically approved in the first quarter.
Non-employee directors receive automatic initial and annual stock option and restricted stock unit awards per policy.
No written policies exist on timing of option-like awards, but the Compensation Committee considers material nonpublic information when granting awards.
Awards are not timed to coincide with the release of material nonpublic information, nor is information release timed to affect compensation value.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Taysha Gene Therapies
- TSHA-102 delivers sustained, multi-domain benefits and safety in Rett syndrome, advancing to high-dose trials.TSHA
Status Update3 Feb 2026 - TSHA-102 trials showed strong safety, efficacy, and cash runway into Q4 2026 after $76.8M raise.TSHA
Q2 20241 Feb 2026 - TSHA-102 shows clinical progress, regulatory momentum, and strong cash runway into Q4 2026.TSHA
Q3 202414 Jan 2026 - TSHA-102 Phase II trials completed dosing with strong safety, efficacy, and cash runway into 2026.TSHA
Q4 202423 Dec 2025 - Up to $300M in securities registered to fund gene therapy pipeline, led by Rett syndrome program.TSHA
Registration Filing16 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and expand authorized shares for future needs.TSHA
Proxy Filing2 Dec 2025 - Shareholders to vote on director elections, auditor ratification, and a 75% increase in authorized shares.TSHA
Proxy Filing2 Dec 2025 - Virtual meeting to elect directors, ratify auditor, and expand authorized shares.TSHA
Proxy Filing2 Dec 2025 - Pivotal TSHA-102 trial advances with 100% response, $230M raised, and cash runway into 2028.TSHA
Q2 202523 Nov 2025